Study of ORIC-101 in Combination With Anticancer Therapy
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101
in combination with nab-paclitaxel or other anticancer therapies when administered to
patients with advanced or metastatic solid tumors.